Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydrocortisone - Diurnal

Next Previous
X
Search
Drug Profile

Hydrocortisone - Diurnal

Alternative Names: Alkindi; ALKINDI SPRINKLE; Chronocort; DNL-0200; Efmody; EFMODY; Hydrocortisone extended release - Diurnal; Infacort; Modified-release hydrocortisone

Latest Information Update: 21 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Diurnal
  • Developer Diurnal; EffRx; Emerge Health; Eton Pharmaceuticals; Medison Pharma
  • Class Anti-inflammatories; Antiallergics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenal insufficiency; Congenital adrenal hyperplasia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Adrenal insufficiency; Congenital adrenal hyperplasia

Most Recent Events

  • 14 May 2024 Efficacy data from phase III extension study for Congenital adrenal hyperplasia released by Neurocrine Biosciences
  • 18 Oct 2023 Diurnal Limited completes a phase II trial in Adrenal insufficiency (In adults) in United Kingdom and Germany (PO) (NCT05222152) (EudraCT2021-000144-21)
  • 15 Jun 2023 The European Commission approves a MAA for Congenital adrenal hyperplasia in EU

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top